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Abstract Phosphodiesterase 4 (PDE4) and phosphodiesterase 7 (PDE7), 
members of PDE super family, catalyse metabolism of secondary 
messenger cyclic adenosine monophosphate leading to augmented 
inflammatory processes in pro-inflammatory and immune-modulatory 
cells. Dual inhibitors of PDE4/7 are a novel class of drug candidates which 
can regulate pro-inflammatory as well as function of immune T-cell and are 
particularly beneficial for the treatment of various inflammatory diseases 
devoid of unwanted actions. Intense efforts have been directed towards 
the development of effective dual inhibitors of both PDE4 and PDE7, but 
not much success has been reported till yet. The aim of present study was 
to design some newer substituted thiazolidine-2-one derivatives as dual 
inhibitors of PDE4/7 using structure based rational drug design approach.A 
new series of thiazolidine-2-one analogues were designed and molecular 
docking was performed using AutoDock Vina to explore the bonding 
interactions of the designed molecules with the amino acid residues in 
the active site of target proteins. The docking study indicated that all 
the substituted thiazolidine-2-one derivatives have appreciable binding 
interactions with protein residues of both PDE4 and PDE7. The newly 
designed compounds could be used as lead molecules for development 
potent and non-toxic dual inhibitors of PDE4/7 for the management of 
various inflammatory conditions. 








Phosphodiesterase 4 (PDE4) and phosphodiesterase 7 (PDE7) belong to the 
cyclic nucleotide PDE super family and catalyse the metabolism of cyclic 
adenosine monophosphate (cAMP) to its inactive metabolite AMP (Conti 
et al., 2003). Intracellular secondary messenger, cAMP regulates many 
biological responses in humans like inflammation, lipid metabolism and 
apoptosis. cAMP is believed to help in maintaining homeostasis of immune 
system by promoting secretion of anti-inflammatory intermediates as well as 
suppressing the secretion of pro-inflammatory intermediates by the cells of 
immune system. A wide range of anti-inflammatory effects such as decreased 
proliferative response, decreased pro-inflammatory cytokine production, and 
decreased surface marker expression in leukocytes can be achieved through 
elevation of intracellular cAMP levels (Souness et al., 2000; Castro et al., 
2005; Baumer et al., 2007). PDE4 enzyme is mainly expressed in every 
pro-inflammatory and immunomodulatory cell (Giembycz, 2002; Tasken 
& Aandahl, 2004). The inhibition of PDE4 results in increased levels of 
intracellular cAMP in inflammatory cells which activate some particular protein 
kinase cascade leading to a wide range of anti-inflammatory responses(Caron 
& Vazquez, 2001; Burnouf & Pruniaux, 2002; Sanz et al., 2005; Press & 
Banner, 2009; Felding et al., 2014). Amongst the wide variety of small 
molecule PDE4 inhibitors, rolipram, cilomilast, roflumilast and apremilast are 
some of the most characterized PDE4 inhibitors to date (Kodimuthali et al., 
2008; Man et al., 2009; Beghè et al., 2013). Roflumilast and apremilast were 
permitted by the Food and Drug Administration as oral drugs for management 
of chronic obstructive pulmonary disease and psoriatic arthritis in 2011 
and 2014, respectively (Guariento et al., 2017; Grewal et al., 2017). PDE7 
inhibition leads to increased levels of cAMP resulting in decrease in oedema, 
cellular inflammation, mucous secretion and bronchoconstriction. Efficacy of 
the inhibitors of PDE7 enzyme has been reported recently in animal models as 
anti-inflammatory agents and represents a new class of drugs the management 
of various inflammatory disorders (Gil et al., 2008; Redondo et al., 2012; 
Grewal et al., 2017a). BRL50481 (3-(N,N-dimethylsulfonamido)-4-methyl-
nitrobenzene) is the only officially available selective inhibitor of PDE7 which 
was discovered in 2004 (Smith et al., 2004; Christensen et al., 2012). 
Dual PDE4/7 inhibitors could be valuable for the treatment of a variety 
of immune and inflammatory disorders devoid of unwanted adverse effects. 
The dual inhibitors of PDE4/7 inhibit the T-cell component of a disorder, 
at least to some extent due to inhibition of PDE7 enzyme, and possess anti-
inflammatory activity, elicited due to inhibition of PDE4 enzyme. In addition, 
dual inhibitors of PDE4/7 could produce more potent activity than the selective 
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PDE4 or PDE7 inhibitor for management of a large range of immunity and 
inflammatory disorders due to a synergetic action with lesser unwanted actions. 
This concept of synergetic effect is supported by the coincidental expression 
of PDE4 and PDE7 subtypes in various immunity and inflammatory cells 
(Castro et al., 2005; Lakics et al., 2010; Vávrová, 2016; Levy et al., 2016).
Various dual inhibitors of PDE4/7 developed include pyrazolo[3,4-b]pyridine 
derivatives, purine derivatives, pyrimidine derivatives, quinazoline derivatives, 
isochromenones and isoxazolinespirocyclicscaffold based compounds which 
had demonstrated their efficacy in a series of in vitroassays as well as animal 
models and suggest the potential of these compounds for the management of 
a large range of inflammatory diseases (Hatzelmann et al., 2002; Gil et al., 
2008a; Pelcman et al., 2010; Pitts et al., 2002; Rudra et al., 2012; Rudra et al., 
2013; Jankowska et al., 2017).
Figure 1: Pharmacophoric features required for dual PDE4/7 inhibitory 
activity and general structure of novel thiazolidine-2-one derivatives designed 
as potential dual PDE4/7 inhibitors.
Development of dual inhibitors of PDE4/7 will yield novel class of 
therapeutic drugs useful for the management of wide range of inflammatory and 
immune diseases with auniquemode of action. The pharmacophoric features 
required for dual PDE4 and PDE7 inhibitory activity were identified based 
on information from available X-ray crystallographic structures of PDE4-
inhibitors complexes and PDE7-inhibitors complexes from the PDB database. 
In the structure of ligands, H-bond donor is essential for H-bond interaction 
with Asn395 residues of PDE4 protein and H-bond acceptor is essential for 
H-bond interaction with Gln413 residue of PDE7 protein. Aromatic ring is 
also required attached to the main ring for hydrophobic interactions with the 
amino acid residues of PDE4 and PDE7 proteins. Several five membered 
heterocyclic derivatives were developed as PDE4 and PDE7 inhibitors such 
as pyrrolidine derivatives, thiazole derivatives, thiadiazoles, isoxazoles, and 
furan derivatives (Nichols et al., 2006; Vergne et al., 2004; Vergne et al., 
2004a; Rudra et al., 2013; Jankowska et al., 2017). Considering the concept 
of bioisosterism (replacing carbon atom with that of sulphur atom) and the 






recognizing the potential role of heterocyclic compounds in wide therapeutic 
areas including inflammation we have designed some novel thiazolidine-2-
one derivatives (Figure 1) asdual PDE4/7 inhibitors using molecular docking 
studies of designed molecules.
2. EXPERIMENTAL
Molecular docking was performed for the designed molecules in the binding site 
of both PDE4 and PDE7 proteins using AutoDock Vina (Trott & Olson, 2010) 
and the graphical user interface, AutoDock Tools (Morris et al., 2009).The 2-D 
chemical structures of the ligands were prepared by Marvin Sketch (Marvin 
15.9.21, 2015, ChemAxon) and converted to 3-D by Frog2 server based on a 
graph decomposition of the compounds coupled with an identification of the 
stereo-centres for which the chirality is unspecified (Miteva et al., 2010). The 
ligands were converted to PDBQT files from MOL format using AutoDock 
Tools. After assessing a numbers of co-crystallized structures of PDE4 and 
PDE7 available in the protein data bank (http://www.rcsb.org/pdb), the best 
ligand bound complexes (PDB entry: 3HMV and 4PM0 for PDE4 and PDE7, 
respectively) were selected with complexes having maximum resolution and best 
binding interactions between ligands and proteins. The PDB files of the target 
proteins were edited using PyMOL (The PyMOL Molecular Graphics System, 
Version 1.7.4.5 Edu, Schrödinger, LLC.) by removing complexed inhibitor, all 
the water molecules as well as all non-interacting ions. The PDBQT files of 
target proteins were generated from the PDB files using AutoDock Tools and 
all the polar hydrogen atoms were added to the protein molecule. The “Grid” 
of AutoDock Tools was used for calculating the grid parameters and all the 
data regarding target protein, ligand, grid size and geometry were saved in 
TXT file. The reference ligands were docked in the active site of target proteins 
and compared with that of the co-crystallized inhibitors for determining the 
accuracy of the docking protocol. The prepared ligand molecules were docked 
in the active site of the refined PDE4 and PDE7 models utilizing AutoDock 
Vina and scored by using scoring function. The binding free energy (ΔG) for 
each ligand was reported in log file. PyMOL was utilized for the analysis of the 
binding interactions (including H-bond and hydrophobic interactions) of the 
ligands in the active site of target proteins.
3. RESULTS AND DISCUSSION
In silico studies were performed to explore the affinity and binding interactions 
of the designed compounds in the active site of both PDE4 and PDE7 proteins 
(PDB entry: 3HMV and 4PM0 for PDE4 and PDE7, respectively). The 
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reference ligands were docked into the active site of PDE4 and PDE7; and the 
docked reference inhibitors of PDE4 and PDE7 produced a similar binding 
pattern and superposition on the binding mode of co-crystallized inhibitors 
validating accuracy of docking methodology. All the designed thiazolidine-2-
one analogues were docked in the active site of PDE4 and PDE7 proteins; and 
most of the designed molecules displayed considerable binding interactions 
in the active site of both PDE4 and PDE7 proteins and stability of the ligand-
protein complex was determined by analysing binding free energy (ΔG, kcal/
mol) of the best docked poses (Table 1).
Table 1: Molecular propertiesand docking score of best-docked poses of 
designed thiazolidine-2-one derivatives (1-18).












1 C10H11NOS 193.26 2.14 1 1 –7.1 –6.3
2 C10H11NO2S 209.26 1.85 2 2 –7.2 –6.7
3 C10H11NO2S 209.26 1.85 2 2 –7.3 –7.8
4 C10H11NO3S 225.26 1.57 3 3 –7.5 –7.0
5 C11H13NO3S 239.29 1.60 3 2 –7.9 –7.5
6 C11H13NO3S 239.29 1.60 3 2 –7.8 –7.1
7 C12H15NO3S 253.32 1.63 3 1 –7.6 –7.0
8 C13H15NO3S 253.32 1.94 3 2 –7.8 –7.3


















10 C14H19NO3S 281.37 2.32 3 1 –7.5 –7.6
11 C13H17NO3S 267.34 1.98 3 1 –7.7 –6.7
12 C13H17NO3S 267.34 1.98 3 1 –7.4 –6.6
13 C15H19NO3S 293.38 2.79 3 2 –8.7 –7.8
14 C15H19NO3S 293.38 2.79 3 2 –8.4 –7.8
15 C16H21NO3S 307.41 2.82 3 1 –8.2 –6.9
16 C16H21NO3S 307.41 2.82 3 1 –8.6 –7.0
17 C17H23NO3S 321.44 3.16 3 1 –8.3 –7.0
18 C17H23NO3S 321.44 3.16 3 1 –8.2 –7.1
#Log P, HBA, HBD, and Mol. Wt., were calculated by Marvin tools of Marvin Sketch v5.5.
Based on the lowest docking free energy and better binding interactions in 
the active site of PDE4 protein, compounds 3, 7, 10, 11, 13 and 18 were further 
analysed in details by PyMOL. The binding poses showing bonding interactions 
(Hydrogen bonds) and overlays of the selected molecules with that of the PDB 
ligand of 3HMV in the active site of PDE4 protein are presented in figures 2and 
3. The docked pose of the selected compounds 3, 7, 10, 11, 13 and 18 showed 
H-bonding interaction between -NH of thiazolidine-2-one ring of the selected 
compounds and carbonyl group at Asn395 residue of the PDE4 protein with bond 
length of 2.9, 3.6, 3.7, 3.6, 3.3 and 2.9 Å, respectively (Figure 2). The substituted 
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phenyl ring of the selected compounds projected in the hydrophobic pocket 
displaying the hydrophobic interactions with Phe446 residue whereas thiazolidine-
2-one ring showed hydrophobic interaction with Met347 residue of PDE4 protein. 
The selected compounds (3, 7, 10, 11, 13 and 18) showed similar binding pattern 
and best fit in the active site of the PDE4 protein as that of co-crystallized ligand 
of PDB 3HMV as seen in the overlay of the selected compounds with the PDB 
Ligand of 3HMV (Figure 3). The docking of the designed molecules in the active 
site of PDE4 protein thus helped us in predicting that the designed thiazolidine-2-




Figure 2: Docked poses showing H-bond interactions for compounds 3 (a), 7 






Figure 3: Overlay of the docked pose of compounds 3 (a), 7 (b), 10 (c), 11 (d), 13 
(e) and 18 (f) with that of PDB Ligand of 3HMV in the active site of PDE4 protein.
In Silico Designing 
of Novel 
Thiazolidine-2-one 





Figure 4: Docked poses showing H-bond interactions for compounds 3 (a), 






Figure 5: Overlay of the docked pose of compounds 3 (a), 4 (b), 7 (c), 10 (d), 
11 (e) and 14 (f) with that of PDB Ligand of 4PM0 in the active site of PDE7 
protein.
4. CONCLUSION 
The present study has been intended to design some newer thiazolidine-2-one 
derivatives as dual inhibitors of PDE4/7, which can be developed further for 
their therapeutic benefits in a wide range of inflammatory diseases. Structure 
based drug design approach was used to design the newer thiazolidine-2-one 
derivatives by using the X-ray crystallographic data of PDE4 and PDE7 proteins 
from protein data bank. Based on pharmacophoric requirements for PDE4 
and PDE7 binding, thiazolidine-2-one scaffold was selected for the design of 
novel analogues by suitable substitutions at the five membered heterocyclic 
ring. Amongst the docked thiazolidine-2-one derivatives, compounds 3, 7, 
10 and 11 showed better binding interactions with both PDE4 and PDE7 
enzymes indicating that these compounds could act as potential dual inhibitors 
of PDE4/7. Overall, the newly designed compounds could be used as lead 
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molecules for development potent and non-toxic dual inhibitors of PDE4/7 for 
the management of various inflammatory conditions.
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